ClinicalTrials.gg
CompletedNCT04117711Updated May 30, 2024Results posted

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

A Phase 1/2 interventional study of AT-007 and Placebo in Classic Galactosemia, sponsored by Applied Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by Applied Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a first-in-human, randomized, placebo-controlled, 4-Part, single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy adult subjects and adult subjects with Classic Galactosemia.

Read the detailed description

The study is designed to assess the safety and PK of AT-007 in healthy subjects and subjects with Classic Galactosemia as well as the effect of AT-007 on biomarkers of galactose metabolism (galactose, galactitol, and other galactose metabolites) in subjects with Classic Galactosemia.

This study consists of 4 parts:

  • Part A (SAD) in 32 healthy subjects. Once daily oral escalating dose (6 active, 2 placebo).
  • Part B and C (MAD for 7 days) in 36 healthy subjects. Once daily multiple daily dosing (8 active, 2 placebo per each dose cohort).
  • Part D (SAD followed by MAD for 27 days) in 18 subjects with Classic Galactosemia. Once daily followed by multiple daily oral dosing (6 active, 2 placebo for each dose cohort).
02

Conditions studied

  • Classic Galactosemia

Keywords

  • Classic Galactosemia
  • Aldose Reductase Inhibition
  • Galactose, Galactitol
03

In context

Lead sponsor

Applied Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Classic Galactosemia confirmed by evidence of absent or significantly decreased (\<1%) GALT activity in red blood cells and by GALT gene analysis
  • Urine galactitol >100 mmol/mol creatinine
  • Galactose-restricted diet

Exclusion criteria

Exclusion Criteria:

  • Complications of CG resulting in disability that, in the opinion of the Investigator, may prevent the subject from completing all study requirements (e.g., severe neurological deficits, severe cognitive impairment, or severe language difficulty).
  • Renal disease ( \< 90 mL/min/1.73 m2 or albuminuria).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    AT-007

    AT-007 is a CNS and retina penetrant aldose reductase inhibitor.

    Drug: AT-007

  • Placebo comparator
    Placebo Comparator

    Placebo is used as a comparator to the experimental arm.

    Drug: Placebo

Interventions

  • DrugAT-007

    AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.

    Also known as: Govorestat

  • DrugPlacebo

    Matching placebo will be administered once in the morning before breakfast

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    To evaluate the safety and tolerability of AT-007 after administration to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.

    Time frame: Events after 1 day of administration.

  2. Number of Participants With Treatment-emergent Adverse Events

    To evaluate the safety and tolerability of AT-007 after multiple ascending doses are administered to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results. Part B and Part C are combined.

    Time frame: 7 Days after Dosing

  3. Number of Participants With Treatment-emergent Adverse Events

    To evaluate the safety and tolerability of AT-007 after multiple doses administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.

    Time frame: 28 Days of Dosing

  4. Number of Participants With Treatment-emergent Adverse Events

    To evaluate the safety and tolerability of AT-007 administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.

    Time frame: 90 Days after Dosing

Secondary outcomes

  1. Cmax of AT-007

    Maximum (peak) plasma drug concentration

    Time frame: Part A: Sampling- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs Parts B, C, D: Day of Last Dose for each Part- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs D Extension: Day 30, 60, 90- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs

  2. Tmax of AT-007

    Time to reach maximum (peak) plasma drug concentration

    Time frame: Part A: Sampling- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs Parts B, C, D: Day of Last Dose for each Part- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs D Extension: Day 30, 60, 90- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs

  3. t1/2 of AT-007

    Terminal elimination half life

    Time frame: Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Parts B, C, D: Determined using Day of Last Dose for the respective Part; predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.

  4. AUClast of AT-007

    Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration

    Time frame: Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Parts B, C, D: Determined using Day of Last Dose for the respective Part at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.

  5. AUCinf of AT-007

    Area under the plasma concentration-time curve from time zero extrapolated to infinity

    Time frame: Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Part D: Determined using Day 1 with sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.

  6. Maximal Galactitol Reduction in Plasma

    Disease-Specific Biomarker in Classic Galactosemia Patients

    Time frame: Part D: Samples at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours on days 1, 12, 32. Part D Extension: Samples at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours on days 1, 30, 60, & 90.

  7. Galactose Concentration in Plasma

    Disease-Specific Biomarker in Classic Galactosemia Patients

    Time frame: Part D: Day 32. Part D Extension: Days 30, 60, & 90.

  8. Galactose-1-Phosphate (Gal-1p) Concentration in Plasma

    Disease-Specific Biomarker in Classic Galactosemia Patients

    Time frame: Part D: Day 32. Part D Extension: Days 30, 60, & 90.

07

Results

Posted May 30, 2024

Participant flow

Part A Cohort 1
Participant flow — Part A Cohort 1
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started6000000000000000000000
Completed6000000000000000000000
Not completed0000000000000000000000
Part A Cohort 2
Participant flow — Part A Cohort 2
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0600000000000000000000
Completed0600000000000000000000
Not completed0000000000000000000000
Part A Cohort 3
Participant flow — Part A Cohort 3
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0060000000000000000000
Completed0060000000000000000000
Not completed0000000000000000000000
Part A Cohort 4
Participant flow — Part A Cohort 4
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0006000000000000000000
Completed0006000000000000000000
Not completed0000000000000000000000
Part A Cohort 5
Participant flow — Part A Cohort 5
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000600000000000000000
Completed0000600000000000000000
Not completed0000000000000000000000
Part A Placebo Comparator
Participant flow — Part A Placebo Comparator
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started00000100000000000000000
Completed00000100000000000000000
Not completed0000000000000000000000
Part B & C AT-007 5mg/kg Cohort
Participant flow — Part B & C AT-007 5mg/kg Cohort
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000006000000000000000
Completed0000006000000000000000
Not completed0000000000000000000000
Part B & C AT-007 10mg/kg Cohort
Participant flow — Part B & C AT-007 10mg/kg Cohort
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000800000000000000
Completed0000000800000000000000
Not completed0000000000000000000000
Part B & C AT-007 20mg/kg Cohort
Participant flow — Part B & C AT-007 20mg/kg Cohort
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started00000000100000000000000
Completed0000000090000000000000
Not completed0000000010000000000000
Part B & C AT-007 40mg/kg
Participant flow — Part B & C AT-007 40mg/kg
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000009000000000000
Completed0000000007000000000000
Not completed0000000002000000000000
Part B & C Placebo Comparator
Participant flow — Part B & C Placebo Comparator
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000800000000000
Completed0000000000800000000000
Not completed0000000000000000000000
Part D Cohort 1
Participant flow — Part D Cohort 1
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000031110000000
Completed0000000000031110000000
Not completed0000000000000000000000
Part D Cohort 2
Participant flow — Part D Cohort 2
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000000003100000
Completed0000000000000003100000
Not completed0000000000000000000000
Part D Cohort 3
Participant flow — Part D Cohort 3
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000000000010000
Completed0000000000000000010000
Not completed0000000000000000000000
Part D Placebo Comparator
Participant flow — Part D Placebo Comparator
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000000000004000
Completed0000000000000000004000
Not completed0000000000000000000000
Part D Extension Cohort 1
Participant flow — Part D Extension Cohort 1
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000000000000900
Completed0000000000000000000700
Not completed0000000000000000000200
Part D Extension Cohort 2
Participant flow — Part D Extension Cohort 2
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000000000000020
Completed0000000000000000000000
Not completed0000000000000000000020
Part D Extension Placebo Comparator
Participant flow — Part D Extension Placebo Comparator
MilestonePart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo ComparatorPart B & C: AT-007 5mg/kgPart B & C: AT-007 10mg/kgPart B & C: AT-007 20mg/kgPart B & C: AT-007 40mg/kgPart B &C: Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kgPart D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D: Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension: Placebo Compartor
Started0000000000000000000004
Completed0000000000000000000003
Not completed0000000000000000000001

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events

To evaluate the safety and tolerability of AT-007 after administration to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.

Time frame:
Events after 1 day of administration.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A: Placebo Comparator
Number of Participants With Treatment-emergent Adverse Events100212
PrimaryNumber of Participants With Treatment-emergent Adverse Events

To evaluate the safety and tolerability of AT-007 after multiple ascending doses are administered to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results. Part B and Part C are combined.

Time frame:
7 Days after Dosing
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart B & C AT-007 5mg/kg CohortPart B & C AT-007 10mg/kg CohortPart B & C AT-007 20mg/kg CohortPart B & C AT-007 40mg/kg CohortPart B & C Placebo Comparator
Number of Participants With Treatment-emergent Adverse Events12312
PrimaryNumber of Participants With Treatment-emergent Adverse Events

To evaluate the safety and tolerability of AT-007 after multiple doses administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.

Time frame:
28 Days of Dosing
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Placebo Comparator
Number of Participants With Treatment-emergent Adverse Events3122
PrimaryNumber of Participants With Treatment-emergent Adverse Events

To evaluate the safety and tolerability of AT-007 administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.

Time frame:
90 Days after Dosing
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: AT-007 40mg/kgPart D Extension Placebo Comparator
Number of Participants With Treatment-emergent Adverse Events712
SecondaryCmax of AT-007

Maximum (peak) plasma drug concentration

Time frame:
Part A: Sampling- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs Parts B, C, D: Day of Last Dose for each Part- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs D Extension: Day 30, 60, 90- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs
Reported as:
Geometric mean · microgram/mL
Cmax of AT-007
microgram/mLPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart B & C Cohort 1: AT-007 5mg/kgPart B & C Cohort 2: AT-007 10mg/kgPart B & C Cohort 3: AT-007 20mg/kgPart B & C Cohort 4: AT-007 40mg/kgPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Extension Cohort 1: AT-007 20mg/kg DAY 30Part D Extension Cohort 1: AT-007 20mg/kg DAY 60Part D Extension Cohort 1: AT-007 20mg/kg DAY 90Part D Extension Cohort 2: AT-007 40mg/kg DAY 30
Cmax of AT-0071.53 ± 55.28.92 ± 31.415.2 ± 49.527 ± 10357.4 ± 23.215.2 ± 45.023.0 ± 39.047.8 ± 35.472.8 ± 44.913.7 ± 34.039.9 ± 70.867.9 ± 68.048.6 ± 21.848.0 ± 24.444.1 ± 36.570.8 ± NA
SecondaryTmax of AT-007

Time to reach maximum (peak) plasma drug concentration

Time frame:
Part A: Sampling- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs Parts B, C, D: Day of Last Dose for each Part- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs D Extension: Day 30, 60, 90- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs
Reported as:
Median · hours
Tmax of AT-007
hoursPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart B & C Cohort 1: AT-007 5mg/kgPart B & C Cohort 2: AT-007 10mg/kgPart B & C Cohort 3: AT-007 20mg/kgPart B & C Cohort 4: AT-007 40mg/kgPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Extension Cohort 1: AT-007 20mg/kg DAY 30Part D Extension Cohort 1: AT-007 20mg/kg DAY 60Part D Extension Cohort 1: AT-007 20mg/kg DAY 90Part D Extension Cohort 2: AT-007 40mg/kg DAY 30
Tmax of AT-0074.00 (4.00 to 6.02)4.00 (2.00 to 4.00)4.00 (4.00 to 4.00)4.00 (4.00 to 24.1)4.00 (4.00 to 8.00)4.00 (4.00 to 8.00)3.96 (2.00 to 8.00)4.00 (4.00 to 8.00)4.00 (4.00 to 6.07)4.00 (2.00 to 6.00)4.96 (4.00 to 8.00)4.00 (1.92 to 8.00)4.03 (1.97 to 8.02)4.01 (2.00 to 7.97)4.00 (2.00 to 4.33)4.17 (4.17 to 4.17)
Secondaryt1/2 of AT-007

Terminal elimination half life

Time frame:
Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Parts B, C, D: Determined using Day of Last Dose for the respective Part; predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.
Reported as:
Geometric mean · hours
t1/2 of AT-007
hoursPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart B & C Cohort 1: AT-007 5mg/kgPart B & C Cohort 2: AT-007 10mg/kgPart B & C Cohort 3: AT-007 20mg/kgPart B & C Cohort 4: AT-007 40mg/kgPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kg
t1/2 of AT-00713.7 ± 45.322.0 ± 92.610.3 ± 31.78.42 ± NA8.2 ± 7.5513.1 ± 39.515.7 ± 79.99.76 ± 22.49.96 ± 27.413.9 ± 11.016.8 ± 56.616.1 ± 21.1
SecondaryAUClast of AT-007

Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration

Time frame:
Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Parts B, C, D: Determined using Day of Last Dose for the respective Part at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.
Reported as:
Geometric mean · microgram*hour/mL
AUClast of AT-007
microgram*hour/mLPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart B & C Cohort 1: AT-007 5mg/kgPart B & C Cohort 2: AT-007 10mg/kgPart B & C Cohort 3: AT-007 20mg/kgPart B & C Cohort 4: AT-007 40mg/kgPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kg
AUClast of AT-00712.6 ± 44.789.0 ± 18.5158 ± 35.0352 ± 75.0624 ± 28.0181 ± 44.3311 ± 47.4592 ± 26.91110 ± 50.2172 ± 25.3698 ± 21.81006 ± 62.3
SecondaryAUCinf of AT-007

Area under the plasma concentration-time curve from time zero extrapolated to infinity

Time frame:
Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Part D: Determined using Day 1 with sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.
Reported as:
Geometric mean · microgram*hour/mL
AUCinf of AT-007
microgram*hour/mLPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kg
AUCinf of AT-00714.3 ± 43.781.8 ± 15.1169 ± 35.3163 ± NA655 ± 0.45109 ± 28.2518 ± 65.21327 ± 17.2
SecondaryMaximal Galactitol Reduction in Plasma

Disease-Specific Biomarker in Classic Galactosemia Patients

Time frame:
Part D: Samples at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours on days 1, 12, 32. Part D Extension: Samples at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours on days 1, 30, 60, & 90.
Reported as:
Mean · maximal change from baseline in ng/mL
Maximal Galactitol Reduction in Plasma
maximal change from baseline in ng/mLPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension AT-007 20mg/kgPart D Extension Placebo Comparator
Maximal Galactitol Reduction in Plasma-475 ± 305-1175 ± 239-1259 ± 220-393 ± 239-974.4 ± 322.42-344.0 ± 449.67
SecondaryGalactose Concentration in Plasma

Disease-Specific Biomarker in Classic Galactosemia Patients

Time frame:
Part D: Day 32. Part D Extension: Days 30, 60, & 90.
Reported as:
Mean · percent change from baseline
Galactose Concentration in Plasma
percent change from baselinePart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension AT-007 20mg/kg Day 30Part D Extension AT-007 20mg/kg Day 60Part D Extension AT-007 20mg/kg Day 90Part D Extension Placebo Comparator Day 30Part D Extension Placebo Comparator Day 60Part D Extension Placebo Comparator
Galactose Concentration in Plasma8.94 ± 8.71-27.8 ± 29.325.4 ± 69.539.8 ± 62.7-153.78 ± 381.47552.29 ± 170.75330.42 ± 102.15139.75 ± 273.41898.67 ± 132.115130.00 ± 101.059
SecondaryGalactose-1-Phosphate (Gal-1p) Concentration in Plasma

Disease-Specific Biomarker in Classic Galactosemia Patients

Time frame:
Part D: Day 32. Part D Extension: Days 30, 60, & 90.
Reported as:
Mean · percent change from baseline
Galactose-1-Phosphate (Gal-1p) Concentration in Plasma
percent change from baselinePart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension AT-007 20mg/kg Day 30Part D Extension AT-007 20mg/kg Day 60Part D Extension AT-007 20mg/kg Day 90Part D Extension Placebo Comparator Day 30Part D Extension Placebo Comparator Day 60Part D Extension Placebo Comparator
Galactose-1-Phosphate (Gal-1p) Concentration in Plasma5.71 ± 15.731.5 ± 6.787.86 ± 21.025.2 ± 8.7433.1 ± 51.12316.04 ± 43.2184.87 ± 24.9178.63 ± 24.47314.03 ± 13.18111.97 ± 21.511

Adverse events

Collected over Part A: 1 day; Part B&C: 7 days; Part D: 32 days; Part D Extension: 90 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Cohort 1: AT-007 0.5mg/kg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A Cohort 2: AT-007 5mg/kg0/6 (0%)0/6 (0%)0/6 (0%)
Part A Cohort 3: AT-007 10mg/kg0/6 (0%)0/6 (0%)0/6 (0%)
Part A Cohort 4: AT-007 20mg/kg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part A Cohort 5: 40mg/kg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A Placebo Comparator0/10 (0%)0/10 (0%)2/10 (20%)
Part B & C Cohort 1: AT-007 5mg/kg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part B & C Cohort 2: AT-007 10mg/kg0/8 (0%)0/8 (0%)2/8 (25%)
Part B & C Cohort 3: AT-007 20mg/kg0/10 (0%)0/10 (0%)3/10 (30%)
Part B & C Cohort 4: AT-007 40mg/kg0/9 (0%)0/9 (0%)1/9 (11.1%)
Part B & C Placebo Comparator0/8 (0%)0/8 (0%)2/8 (25%)
Part D Cohort 1: AT-007 5mg/kg0/4 (0%)0/4 (0%)3/4 (75%)
Part D Cohort 2: AT-007 20mg/kg0/4 (0%)0/4 (0%)1/4 (25%)
Part D Cohort 3: AT-007 40mg/kg0/4 (0%)0/4 (0%)2/4 (50%)
Part D Placebo Comparator0/6 (0%)0/6 (0%)2/6 (33.3%)
Part D Extension Cohort 1: 20mg/kg0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Part D Extension Cohort 2: 40mg/kg0/2 (0%)0/2 (0%)1/2 (50%)
Part D Extension Placebo Comparator0/4 (0%)0/4 (0%)2/4 (50%)
Most frequent serious events
Most frequent serious events
EventPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: 40mg/kgPart A Placebo ComparatorPart B & C Cohort 1: AT-007 5mg/kgPart B & C Cohort 2: AT-007 10mg/kgPart B & C Cohort 3: AT-007 20mg/kgPart B & C Cohort 4: AT-007 40mg/kgPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Cohort 1: 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension Placebo Comparator
Liver InjuryHepatobiliary disorders0/60/60/60/60/60/100/60/80/100/90/80/40/40/40/61/90/20/4
Most frequent other events
Most frequent other events
EventPart A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: 40mg/kgPart A Placebo ComparatorPart B & C Cohort 1: AT-007 5mg/kgPart B & C Cohort 2: AT-007 10mg/kgPart B & C Cohort 3: AT-007 20mg/kgPart B & C Cohort 4: AT-007 40mg/kgPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 2: AT-007 20mg/kgPart D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Cohort 1: 20mg/kgPart D Extension Cohort 2: 40mg/kgPart D Extension Placebo Comparator
ALT IncreasedHepatobiliary disorders0/60/60/60/61/60/100/61/80/100/91/80/40/40/40/61/91/20/4
Infections/InfestationsInfections and infestations1/60/60/60/60/60/101/60/80/100/90/82/40/41/40/60/90/21/4
Gastrointestinal DisordersGastrointestinal disorders0/60/60/61/60/61/100/60/81/100/90/81/40/40/41/62/90/21/4
Musculoskelatal & Connective Tissue DisordersMusculoskeletal and connective tissue disorders0/60/60/61/60/61/100/60/80/101/90/80/41/40/41/60/90/21/4
Nervous SystemNervous system disorders0/60/60/61/60/62/100/60/81/100/91/80/41/40/41/61/90/20/4
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications0/60/60/60/60/60/100/60/82/100/90/81/40/40/40/60/90/20/4
InvestigationsInvestigations0/60/60/60/61/60/100/61/80/100/91/80/40/41/40/61/90/20/4
General DisordersGeneral disorders0/60/60/60/60/60/100/60/80/100/90/80/40/40/41/60/90/21/4
Seasonal AllergiesImmune system disorders0/60/60/60/60/60/100/60/80/100/90/80/40/40/40/61/90/20/4
Reproductive System DisorderReproductive system and breast disorders0/60/60/60/60/60/100/60/80/100/90/80/40/40/40/61/90/20/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A Placebo ComparatorPart B & C AT-007 5mg/kg CohortPart B & C AT-007 10mg/kg CohortPart B & C AT-007 20mg/kg CohortPart B & C AT-007 40mg/kg CohortPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg)Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: AT-007 40mg/kgTotal
Median42.5 (37 to 49)54.0 (47 to 58)35.0 (27 to 45)44.0 (39 to 52)31.5 (25 to 43)54.5 (39 to 64)32.5 (29 to 53)35.5 (30 to 40)35.0 (28 to 37)27.0 (23 to 37)37 (33 to 41.5)19.5 (18 to 21)37 (37 to 37)50 (50 to 50)19 (19 to 19)20.5 (19 to 22)28 (28 to 28)43 (43 to 43)32 (23 to 44)29.5 (20 to 41)22.0 (19 to 25)36.0 (22 to 50)NA (NA to NA)
Sex: Female, Male
Sex: Female, Male(Participants)Part A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A Placebo ComparatorPart B & C AT-007 5mg/kg CohortPart B & C AT-007 10mg/kg CohortPart B & C AT-007 20mg/kg CohortPart B & C AT-007 40mg/kg CohortPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg)Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: AT-007 40mg/kgTotal
Female252448534531001100233056
Male414222156452110111216254
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A Placebo ComparatorPart B & C AT-007 5mg/kg CohortPart B & C AT-007 10mg/kg CohortPart B & C AT-007 20mg/kg CohortPart B & C AT-007 40mg/kg CohortPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg)Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: AT-007 40mg/kgTotal
Hispanic or Latino152239436530000000000043
Not Hispanic or Latino514431254453111211449267
Unknown or Not Reported00000000000000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A Placebo ComparatorPart B & C AT-007 5mg/kg CohortPart B & C AT-007 10mg/kg CohortPart B & C AT-007 20mg/kg CohortPart B & C AT-007 40mg/kg CohortPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg)Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: AT-007 40mg/kgTotal
American Indian or Alaska Native10000000100000000000002
Asian00100000000000000000001
Native Hawaiian or Other Pacific Islander00000000000000000000000
Black or African American102321143250000000000024
White463339546733111211449282
More than one race00001000000000000000001
Unknown or Not Reported00000000000000000000000
Region of Enrollment
Region of Enrollment(participants)Part A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A Placebo ComparatorPart B & C AT-007 5mg/kg CohortPart B & C AT-007 10mg/kg CohortPart B & C AT-007 20mg/kg CohortPart B & C AT-007 40mg/kg CohortPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg)Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: AT-007 40mg/kgTotal
United States666661068109831112114492110
Galactitol
Galactitol(ng/mL)Part A Cohort 1: AT-007 0.5mg/kgPart A Cohort 2: AT-007 5mg/kgPart A Cohort 3: AT-007 10mg/kgPart A Cohort 4: AT-007 20mg/kgPart A Cohort 5: AT-007 40mg/kgPart A Placebo ComparatorPart B & C AT-007 5mg/kg CohortPart B & C AT-007 10mg/kg CohortPart B & C AT-007 20mg/kg CohortPart B & C AT-007 40mg/kg CohortPart B & C Placebo ComparatorPart D Cohort 1: AT-007 5mg/kgPart D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg)Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg)Part D Cohort 2: AT-007 20mg/kgPart D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg)Part D Cohort 3: AT-007 40mg/kgPart D Placebo ComparatorPart D Extension Placebo ComparatorPart D Extension Cohort 1: AT-007 20mg/kgPart D Extension Cohort 2: AT-007 40mg/kgTotal
Median———————————2490 (2200 to 2580)2380 (2380 to 2380)2140 (2140 to 2140)2360 (2360 to 2360)2170 (2060 to 2280)2340 (2340 to 2340)2810 (2810 to 2810)2480 (1995 to 3420)2612.5 (1960 to 3670)2300 (1780 to 2775)NA (NA to NA)2434.4 (1950 to 3670)
08

Study locations

4 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • ICON Clinical Research
    San Antonio, Texas 78209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Dec 2021, 29 months.

Results were first posted in May 2024, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2019
First posted
Oct 7, 2019
StartActual
Jun 21, 2019
Primary completionActual
Dec 14, 2021
CompletionActual
Dec 14, 2021
Results first posted
May 30, 2024
Last update
May 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04117711
Lead sponsor
Applied Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2019
Start date
Jun 21, 2019
Primary completion
Dec 14, 2021
Completion
Dec 14, 2021
Results posted
May 30, 2024
Last update
May 30, 2024

Study contacts

Robert Green, MD, MPH
principal investigator · Brigham and Women's Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Govorestat

Start the discussion